These results suggest that an increase in catecholamine productio

These results suggest that an increase in catecholamine production occurs in inflamed joints of CIA. The catecholamines are, at least in part, from Th1 and Th2 cells, and they may be related to joint inflammatory alleviation in CIA progression.”
“To evaluate clinical outcomes and effects of non-surgical periodontal therapy on serum, gingival crevicular fluid (GCF) interleukin-1beta

(IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) levels in chronic periodontitis patients with/without rheumatoid arthritis (RA), fifteen RA patients with chronic periodontitis (RA-P) and 15 systemically healthy non-RA chronic periodontitis patients (H-P) were recruited. LXH254 cell line Clinical periodontal recordings, GCF, and blood samples were obtained at baseline, 1, 3, and 6 months after periodontal treatment. GCF, serum IL-1 beta, TNF-alpha levels were analyzed by ELISA. Disease activity score 28 (DAS28) was used to assess RA selleck products clinical morbidity. Study groups were compared by Mann-Whitney U test. Wilcoxon test was used to compare the data at baseline, 1, 3, and 6 months after periodontal therapy

within the same group. DAS28 decreased significantly after periodontal therapy in RA-P group (p < 0.01). Serum TNF-alpha concentrations of H-P group were significantly higher than those of RA-P group (p < 0.01), whereas IL-1 beta levels were similar. No significant change was observed in serum levels of these cytokines after periodontal therapy. GCF IL-1 beta amounts decreased significantly in both groups following treatment (p < 0.01). At 6-months, H-P GCF IL-1 beta concentrations

were significantly lower than baseline. DAS28 and GCF IL-1 beta correlated with clinical periodontal indices (p < 0.01). Significant decreases in DAS28 and GCF IL-1 beta amounts after periodontal treatment suggest that periodontal therapy synergizes with systemic RA therapy to improve Aldehyde_oxidase RA status.”
“The aim of this study was to compare the performance characteristics of two answer modalities for BASDAI and BASFI in patients with AS and to show validity and reliability of NRS in Turkish version. BASDAI and BASFI were simultaneously employed with a 10-cm VAS and an 11-point NRS. Internal consistency was assessed by using Cronbach’s alpha coefficients. Testing was performed on baseline and next day under standardized conditions. Construct validity was determined by association of these measures with ASDAS, DFI, global disease activity, pain scores, ASQOL, HAQ, and SF-36. We also tested the ability of NRS version of BASDAI and BASFI to detect changes. A total 114 patients with AS according to the modified New York criteria were included. There was a good agreement between the total scores of each instrument on day 0 (ICC values were 0.894-0.934).

Comments are closed.